Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This randomized controlled trial found that consuming *Gynostemma pentaphyllum* extract significantly improved hair elasticity, density, and diameter over 24 weeks without severe adverse events, suggesting it as a safe functional food ingredient for hair health improvement.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

This study aims to compare the safety and effectiveness of bariatric surgery versus medical care on ovulation rates in women with PCOS and obesity, as current observational data suggests surgery may improve fertility prospects, but no randomized trial has yet confirmed this effect.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study found that combining concentrated growth factor injections with minoxidil treatment significantly improved hair growth and participant satisfaction in male patients with androgenetic alopecia compared to minoxidil alone.

This study found that finasteride reduced prostate cancer incidence by 30%, with no significant difference in Gleason scores compared to placebo after re-evaluation of pathology and extended follow-up.

This review discusses various treatments for benign prostatic hyperplasia, comparing medications like finasteride and terazosin, as well as surgical and placebo options, without presenting new clinical findings.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

This study found a positive association between clinically meaningful scalp hair regrowth and improvements in patient-reported outcomes, such as satisfaction and reduced psychosocial burden.

In this study, ALRV5XR treatment significantly increased terminal hair density in men with androgenetic alopecia after 24 weeks, while also decreasing vellus hair density, and was well tolerated without adverse events, suggesting its potential efficacy over standard therapies.

In this clinical trial, supplementation with Lambdapil® Anti Hair Loss capsules for 6 months significantly improved hair resistance and volume in women and increased the anagen/telogen hair ratio in men, indicating enhanced hair growth compared to the placebo group.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

This study found that an 8-week supplementation with specific probiotic strains improved hormonal markers and oxidative stress while decreasing inflammation in women with PCOS, although clinical symptoms like acne and hirsutism showed no significant improvement compared to the placebo group.

In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.

Baricitinib is a safe and effective treatment for severe alopecia areata.

This study found that curcumin lowered fasting blood sugar levels and improved menstruation characteristics in women with polycystic ovary syndrome, but it did not affect other metabolic, hormonal, or hirsutism indices.

This study found that magnesium supplementation significantly improved overall quality of life in women with polycystic ovary syndrome, but did not significantly affect acne, alopecia, or abnormal uterine bleeding.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This clinical trial found that topical rosuvastatin and melatonin creams significantly reduced the severity of mild to moderate plaque psoriasis over 12 weeks, with a satisfactory safety profile.

This study found that both methotrexate and azathioprine were equally effective and well-tolerated in improving symptoms of lichen planopilaris over six months, with no significant difference between the two treatments in terms of efficacy.

This study found that both 0.01% and 0.03% bimatoprost gel and 2% minoxidil gel significantly improved eyebrow density in individuals with hypotrichosis, with no significant difference between the treatments, although the highest bimatoprost concentration showed a more favorable response.

This study concluded that ALRV5XR treatment significantly increased terminal hair density in both men and women with androgenetic alopecia and telogen effluvium, with more pronounced effects in women.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

This letter discusses the variability in platelet-rich plasma preparation for androgenetic alopecia treatment and highlights that different methods yield varied platelet concentrations but not significant differences in growth factor secretion per platelet.

This study found that reflexology massage significantly improved hair regrowth in women with chemotherapy-induced alopecia compared to those receiving usual care.

Topical treatment SM04554 safely promotes hair growth in male baldness.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

This letter challenges an interpretation of results from a zinc lozenge trial that suggested patient perceptions of receiving treatment might indicate effective blinding, arguing this only holds for crossover studies.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This study found that in healthy young men, oral minoxidil at 5 mg/day led to increased carotid intima-media thickness and vascular aging, suggesting potential cardiovascular side effects at higher doses. A dose-dependent effect was observed, while dutasteride displayed a favorable vascular profile without significant changes.